What was the market valuation of the UK car t-cell-therapy market in 2024?

The market valuation was $554.28 Million in 2024. Read More

What is the projected market valuation for the UK car t-cell-therapy market by 2035?

The projected valuation for 2035 is $2699.76 Million. Read More

What is the expected CAGR for the UK car t-cell-therapy market during the forecast period 2025 - 2035?

The expected CAGR is 15.48% during the forecast period 2025 - 2035. Read More

Which therapeutic area had the highest valuation in the UK car t-cell-therapy market?

Oncology had the highest valuation, ranging from $300.0 Million to $1500.0 Million. Read More

What are the projected valuations for the autologous and allogeneic cell sources in the UK car t-cell-therapy market?

The projected valuation for autologous cell sources is between $250.0 Million and $1200.0 Million, while allogeneic sources range from $200.0 Million to $1000.0 Million. Read More

Which indication is expected to generate significant revenue in the UK car t-cell-therapy market?

Non-Hodgkin Lymphoma is expected to generate significant revenue, with valuations between $250.0 Million and $1200.0 Million. Read More

What is the expected market size for hospitals as end users in the UK car t-cell-therapy market?

The expected market size for hospitals as end users ranges from $221.71 Million to $1100.0 Million. Read More

Who are the key players in the UK car t-cell-therapy market?

Key players include Novartis, Gilead Sciences, Bristol-Myers Squibb, Celgene, Amgen, Merck & Co., AstraZeneca, Juno Therapeutics, and Bluebird Bio. Read More

What is the projected valuation for the infectious diseases segment in the UK car t-cell-therapy market?

The projected valuation for the infectious diseases segment is between $104.28 Million and $499.76 Million. Read More

How do research institutes compare to hospitals in terms of market size in the UK car t-cell-therapy market?

Research institutes are projected to have a market size ranging from $166.28 Million to $800.0 Million, compared to hospitals' range of $221.71 Million to $1100.0 Million. Read More

UK Car T Cell Therapy Market

ID: MRFR/Pharma/48107-HCR

200 Pages

Nidhi Mandole

Last Updated: April 06, 2026

UK CAR T Cell Therapy Market Research Report By Therapeutic Area (Oncology, Autoimmune Diseases, Infectious Diseases), By Cell Source (Autologous, Allogeneic, Gene-Edited), By Indication (Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma, Multiple Myeloma), and By End-user (Hospitals, Research Institutes, Cancer Treatment Centers) - Growth & Industry Forecast 2025 To 2035

UK Car T Cell Therapy Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Therapeutic Area (USD Million)
  1. 4.1.1 Oncology
  2. 4.1.2 Autoimmune Diseases
  3. 4.1.3 Infectious Diseases
2. 4.2 Healthcare, BY Cell Source (USD Million)
  1. 4.2.1 Autologous
  2. 4.2.2 Allogeneic
  3. 4.2.3 Gene-Edited
3. 4.3 Healthcare, BY Indication (USD Million)
  1. 4.3.1 Acute Lymphoblastic Leukemia
  2. 4.3.2 Non-Hodgkin Lymphoma
  3. 4.3.3 Multiple Myeloma
4. 4.4 Healthcare, BY End User (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Research Institutes
  3. 4.4.3 Cancer Treatment Centers
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Gilead Sciences (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Celgene (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Amgen (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Merck & Co. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Juno Therapeutics (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Bluebird Bio (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 UK MARKET ANALYSIS BY THERAPEUTIC AREA
3. 6.3 UK MARKET ANALYSIS BY CELL SOURCE
4. 6.4 UK MARKET ANALYSIS BY INDICATION
5. 6.5 UK MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF HEALTHCARE
9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
12. 6.12 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE)
13. 6.13 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Million)
14. 6.14 HEALTHCARE, BY CELL SOURCE, 2024 (% SHARE)
15. 6.15 HEALTHCARE, BY CELL SOURCE, 2024 TO 2035 (USD Million)
16. 6.16 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
17. 6.17 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Million)
18. 6.18 HEALTHCARE, BY END USER, 2024 (% SHARE)
19. 6.19 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
  2. 7.2.2 BY CELL SOURCE, 2025-2035 (USD Million)
  3. 7.2.3 BY INDICATION, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK Healthcare Market Segmentation

Healthcare By Therapeutic Area (USD Million, 2025-2035)

Oncology
Autoimmune Diseases
Infectious Diseases

Healthcare By Cell Source (USD Million, 2025-2035)

Autologous
Allogeneic
Gene-Edited

Healthcare By Indication (USD Million, 2025-2035)

Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma

Healthcare By End User (USD Million, 2025-2035)

Hospitals
Research Institutes
Cancer Treatment Centers

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”